Infliximab

Excerpt

This activity discusses the mechanism of action and clinical applications of infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). This FDA-approved therapy addresses inflammatory conditions, including Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and severe plaque psoriasis. The program details infliximab's pharmacokinetics, dosing considerations, contraindications, and monitoring protocols, offering healthcare professionals a comprehensive understanding essential for personalized patient care. Highlighting the significance of an interprofessional approach, this initiative emphasizes the collaborative effort necessary to navigate infliximab therapy effectively. This educational endeavor aims to optimize treatment strategies, mitigate adverse events, and enhance clinical outcomes across diverse patient populations by empowering healthcare professionals with evidence-based insights.